This study investigated treatment characteristics of Guillain-Barré syndrome (GBS) in a real-world setting between 2000 and 2019. We analyzed clinical improvement between nadir and last follow-up in patients with severe GBS (defined as having a GBS disability scale > 2 at nadir) and aimed to detect clinical factors associated with multiple treatments. We included 121 patients (74 male; median age 48 [IQR 35–60]) with sensorimotor (63%), pure motor (15%), pure sensory (10%) and localized GBS (6%) as well as Miller Fisher syndrome (6%). 44% of patients were severely affected. All but one patient received at least one immunomodulatory treatment with initially either intravenous immunoglobulins (88%), plasma exchange (10%) or corticosteroids (1%), and 25% of patients received more than one treatment. Severe GBS but not age, sex, GBS subtype or date of diagnosis was associated with higher odds to receive more than one treatment (OR 4.22; 95%CI 1.36–13.10; p = 0.01). Receiving multiple treatments had no adjusted effect (OR 1.30, 95%CI 0.31–5.40, p = 0.72) on clinical improvement between nadir and last follow-up in patients with severe GBS. This treatment practice did not change over the last 20 years.

本研究调查了 2000 年至 2019 年真实世界环境中吉兰-巴雷综合征 (GBS) 的治疗特征。我们分析了重度 GBS（定义为 GBS 残疾量表 > 2 at nadir) 并旨在检测与多种治疗相关的临床因素。我们纳入了 121 名患者（74 名男性；中位年龄 48 [IQR 35-60]），患有感觉运动 (63%)、纯运动 (15%)、纯感觉 (10%) 和局部 GBS (6%) 以及 Miller Fisher综合征 (6%)。44% 的患者受到严重影响。除一名患者外，所有患者均接受了至少一种免疫调节治疗，最初是静脉注射免疫球蛋白 (88%)、血浆置换 (10%) 或皮质类固醇 (1%)，25% 的患者接受了不止一种治疗。严重的 GBS 但不是年龄、性别、p  = 0.01）。接受多种治疗对 重度 GBS 患者的最低点和末次随访之间的临床改善没有调整影响（OR 1.30，95%CI 0.31-5.40，p = 0.72）。在过去的 20 年里，这种治疗方法没有改变。